Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Vectus Biosystems Limited ( (AU:VBS) ).
Vectus Biosystems Limited has entered into a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 renal compound, which targets renal fibrosis. The transaction, valued at approximately A$4.5 million, will provide Vectus with shares and pre-funded warrants in XORTX, aligning with its strategy to develop and validate drug candidates for commercial partnerships. This deal allows Vectus to maintain an interest in the compound’s development without further financial input, while continuing to focus on its lead cardiovascular candidate and other emerging fibrosis treatments.
More about Vectus Biosystems Limited
Vectus Biosystems Limited is a company focused on developing treatments for fibrosis, targeting major diseases such as heart, kidney, and liver conditions. Since its ASX listing in 2016, Vectus has been advancing its lead compound, VB0004, which addresses tissue hardening and high blood pressure, through successful pre-clinical trials and human trials.
Average Trading Volume: 54,092
Technical Sentiment Signal: Sell
Current Market Cap: A$3.95M
For a thorough assessment of VBS stock, go to TipRanks’ Stock Analysis page.